A FIRST-IN-HUMAN TRIAL OF AN INTEGRIN BETA-6 TARGETED ANTIBODY-DRUG CONJUGATE (ADC), SGNB6A, IN PATIENTS WITH ADVANCED SOLID TUMORS: INTERIM RESULTS OF A PHASE 1 STUDY (SGNB6A-001)

被引：1

作者：

Hollebecque, Antoine ^{[1
]}

Lopez, Juanita ^{[2
]}

Piha-Paul, Sarina ^{[3
]}

Dowlati, Afshin ^{[4
]}

Patnaik, Amita ^{[5
]}

Galvao, Vladimir ^{[6
]}

Buckorny, Bruno ^{[7
]}

Sehgal, Kartik ^{[8
]}

Kingsley, Edwin ^{[9
]}

Sanborn, Rachel ^{[10
]}

Peters, Solange ^{[11
]}

Sun, Yan ^{[12
]}

Patilea-Vrana, Gabriela ^{[12
]}

Nazarenko, Natalya ^{[12
]}

Calvo, Emiliano ^{[13
]}

机构：

[1] Inst Gustave Roussy, Villejuif, France

[2] Royal Marsden Hosp Surrey, London, England

[3] Univ Texas Houston, Houston, TX USA

[4] Case Western Reserve Univ, Cleveland, OH USA

[5] START San Antonio, San Antonio, TX USA

[6] Vall dHebron Inst Oncol, Barcelona, Spain

[7] Beth Israel Deaconess Med Ctr, Boston, MA USA

[8] Dana Farber Canc Inst, Boston, MA USA

[9] Comprehens Canc Ctr Nevada, Las Vegas, NV USA

[10] Earle A Chiles Res Inst, Portland, OR USA

[11] CHU Vaudois, Lausanne, Switzerland

[12] Seagen Inc, Bothell, WA USA

[13] START Madrid CIOCC, Madrid, Spain

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷

关键词：

D O I：

10.1136/jitc-2022-SITC2022.0731

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

731

引用

页码：A763 / A763

页数：1

共 50 条

[21] First-in-human phase 1, dose-escalation and -expansion study of ABBV-399, an antibody-drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors [J].

Angevin, E. ;

Kelly, K. ;

Heist, R. ;

Morgensztern, D. ;

Weekes, C. ;

Bauer, T. M. ;

Ramanathan, R. K. ;

Nemunaitis, J. ;

Fan, X. ;

Olyaie, O. ;

Parikh, A. ;

Reilly, E. ;

Afar, D. ;

Naumovski, L. ;

Strickler, J. .

ANNALS OF ONCOLOGY, 2016, 27

[22] A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors [J].

Charlotte Lemech ;

Natasha Woodward ;

Nancy Chan ;

Joanne Mortimer ;

Louie Naumovski ;

Silpa Nuthalapati ;

Bo Tong ;

Fang Jiang ;

Peter Ansell ;

Christine K. Ratajczak ;

Jasgit Sachdev .

Investigational New Drugs, 2020, 38 :1815-1825

[23] A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors [J].

Lemech, Charlotte ;

Woodward, Natasha ;

Chan, Nancy ;

Mortimer, Joanne ;

Naumovski, Louie ;

Nuthalapati, Silpa ;

Tong, Bo ;

Jiang, Fang ;

Ansell, Peter ;

Ratajczak, Christine K. ;

Sachdev, Jasgit .

INVESTIGATIONAL NEW DRUGS, 2020, 38 (06) :1815-1825

[24] YL201, a novel B7H3-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors: Results from a first-in-human phase I study [J].

Zhao, H. ;

Ma, Y. ;

Meng, X. ;

Wu, L. ;

Fan, Y. ;

Zheng, Y. ;

Liu, Z. ;

Ji, Y. ;

Lv, D. ;

Luo, S. ;

Sommerhalder, D. ;

Fu, S. ;

Huang, Y. ;

Yang, Y. ;

Fang, W. ;

Zhao, Y. ;

Wang, Y. ;

Chin, S. ;

Xue, T. ;

Zhang, L. .

ANNALS OF ONCOLOGY, 2024, 35 :S485-S485

[25] First-in-human study of SYS6010, a novel EGFR targeting antibody drug conjugate (ADC) for patients with advanced solid tumors Free [J].

Lu, Shun ;

Zhou, Zhen ;

Li, Zi-Ming ;

He, Zhi-Yong ;

Fang, Jian ;

Sun, Hong-Mei ;

Gong, Yi ;

Cheng, Ying ;

Liu, Yi-Bing ;

Yao, Yu ;

Yu, Yan ;

Shang, Yan-Hong ;

Yuan, Xiang-Lin ;

Han, Liang ;

Zhang, Mingjun ;

Yang, Kun-Yu ;

Zhang, Liqiong ;

Wan, Xuechao ;

Qi, Huanhuan ;

Yang, Yang .

CANCER RESEARCH, 2025, 85 (08)

[26] First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors [J].

Garrido-Laguna, Ignacio ;

Krop, Ian ;

Burris, Howard A., III ;

Hamilton, Erika ;

Braiteh, Fadi ;

Weise, Amy M. ;

Abu-Khalaf, Maysa ;

Werner, Theresa L. ;

Pirie-Shepherd, Steven ;

Zopf, Christopher J. ;

Lakshminarayanan, Mani ;

Holland, Jaymes S. ;

Baffa, Raffaele ;

Hong, David S. .

INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (07) :1798-1808

[27] A first-in-human phase 1, multicenter, open-label study of M3554, a novel anti-GD2 antibody-drug conjugate (ADC), in patients with advanced solid tumors Free [J].

Italiano, Antoine ;

Yonemori, Kan ;

Haddox, Candace L. ;

Ahnert, Jordi R. ;

Penel, Nicolas ;

Schoffski, Patrick ;

Habermehl, Christina ;

Sanz, Vanesa P. ;

Demetri, George .

CANCER RESEARCH, 2025, 85 (08)

[28] EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumors [J].

Aggarwal, Charu ;

Azzoli, Christopher G. ;

Spira, Alexander I. ;

Solomon, Benjamin J. ;

Le, Xiuning ;

Rolfo, Christian ;

Planchard, David ;

Felip, Enriqueta ;

Wu, Yi-Long ;

Ahn, Myung-Ju ;

Seiwert, Tanguy Y. ;

Goto, Koichi ;

Azaro, Analia ;

Lissa, Delphine ;

Hamid, Oday ;

McGrath, Lara ;

Maudsley, Rhiannon ;

Arnaldez, Fernanda I. ;

Grenga, Italia ;

Massarelli, Erminia .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

[29] A first-in-human trial of intravesical enfortumab vedotin (EV), an antibody-drug conjugate (ADC), in patients with non-muscle invasive bladder cancer (NMIBC): Interim results of a phase 1 study (EV-104). [J].

Kamat, Ashish M. ;

Lotan, Yair ;

Roupret, Morgan ;

Steinberg, Gary D. ;

Inman, Brant A. ;

Powles, Thomas ;

Redorta, J. Palou ;

Porten, Sima P. ;

Kulkarni, Girish S. ;

Uchio, Edward M. ;

Gorla, Seema Rao ;

Haas, Gabriel P. ;

Yu, Yao ;

Chia, Yen Lin ;

Birrenkott, Matthew ;

Kates, Max R. .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

[30] Phase 1 study of SGN-B7H4V, a novel, investigational vedotin antibody-drug conjugate directed to B7-H4, in patients with advanced solid tumors (SGNB7H4V001, trial in progress) [J].

Patnaik, Amita ;

Lakhani, Nehal J. ;

Xu, Ping ;

Nazarenko, Natalya N. ;

Call, Justin A. .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

← 1 2 3 4 5 →